LDS/Medical Tests/EdenDx Methylation Assay (CDO1 and CELF4) for Early Detection of Endometrial Cancer

EdenDx Methylation Assay (CDO1 and CELF4) for Early Detection of Endometrial Cancer

Endometrial cancer is a significant and growing public health concern, ranking as the fourth most common cancer among women in the United States and the most prevalent malignancy of the female reproductive organs. Endometrial cancer is broadly categorized as Type I and Type II. Type I is estrogen-dependent, generally well-differentiated, and often preceded by endometrial hyperplasia, with a favorable prognosis when detected early. Type II cancers including serous, clear cell, and carcinosarcomas—are estrogen-independent, poorly differentiated, more aggressive, and typically present at a later stage, leading to worse clinical outcomes. Although around 69% of endometrial cancers are currently diagnosed at an early stage, often due to symptoms such as abnormal postmenopausal bleeding, a significant portion of patients, particularly those with aggressive Type II subtypes, are still diagnosed at advanced stages when treatment is less effective, and outcomes are poor.

Currently, diagnosis relies on invasive procedures such as endometrial biopsy as gold standard or dilation and curettage (D&C), which are effective but uncomfortable, costly, and less feasible for routine screening or triage. Transvaginal ultrasound (TVUS) is widely used to evaluate endometrial thickness and exclude malignancy. However, its diagnostic accuracy is limited in premenopausal and perimenopausal women, where hormonal fluctuations can cause physiological variations in endometrial thickness. Another non-invasive method is the liquid biopsy, which includes measurement of serum and cervicovaginal levels of cancer antigen 125 (CA-125). While CA-125 is elevated in some endometrial cancer cases, its use is limited due to low specificity and it can also be elevated in benign gynecological conditions like adenomyosis, fibroids, and endometriosis, making it unsuitable for screening.

Genomic and epigenomic studies have identified recurrent alterations in endometrial cancer, including gene mutations (e.g., PTEN, TP53, POLE, PIK3CA), microsatellite instability (MSI), copy-number variations, and most notably, DNA methylation changes. DNA methylation is particularly attractive as a biomarker due to its early occurrence in carcinogenesis and its high stability in clinical samples such as urine or cervicovaginal fluid.

The EdenDx (Early Detection of Endometrial Neoplasm) test represents a novel and promising non-invasive diagnostic tool for endometrial cancer. EdenDx detects hypermethylation of the CDO1 (Cysteine Dioxygenase Type 1) and CELF4 (CUGBP Elav-Like Family Member 4) genes in bisulfite-converted DNA using real-time PCR. Both genes have been shown to be consistently hypermethylated in endometrial cancer tissues, particularly in endometrioid subtypes, compared to healthy controls. CDO1 is involved in cysteine metabolism and oxidative stress regulation, while CELF4 plays a role in RNA binding and post-transcriptional gene regulation. Aberrant methylation of these genes is associated with tumorigenesis and has demonstrated high diagnostic potential. In preliminary studies, EdenDx demonstrated 87.5% sensitivity and 95.9% specificity in women with postmenopausal bleeding, indicating excellent diagnostic performance.

This in vitro diagnostic assay is intended to aid in the early detection and diagnosis of endometrial cancer in individuals who present with symptoms or are identified as being at increased risk. The EdenDx test qualitatively detects hypermethylation in the CDO1 and CELF4 genes, which are associated with endometrial cancer. A positive result indicates the presence of cells with hypermethylation in one or both genes, suggesting the presence of endometrial cancer. EdenDx is provided in US by Gnosis (Mountain View Medical Laboratory), https://gnosisdx.com/.

  • As an aid in diagnosis of endometrial cancer in symptomatic and high-risk patients
  • As a triage to intrauterine biopsy in high-risk patient and patient with Lynch Syndrome
  • Assist in guiding the management of endometrial hyperplasia, particularly in patients with ambiguous or borderline histological findings
A positive result indicates the presence of methylation, suggesting a higher likelihood of endometrial cancer or precancerous changes. Further evaluation with endometrial biopsy is recommended for definitive diagnosis A negative result indicates the absence of methylation, suggesting a lower likelihood of endometrial cancer or precancerous changes. However, it should not be the sole basis for diagnosis, as false negatives can occur if insufficient cancer cells are present. If symptoms persist, additional diagnostic tests should be considered to rule out cancer.

Negative (Negative for methylation of CDO1 and CELF4)

Real-time multiplex PCR methylation assay.

Endocervical scaping sample collected with brume or brush in liquid cytology (ThinPrep), tissue biopsy (formalin-fixed paraphing embedded tissue).

ThinPrep specimens is stable for 1 month.

FFPE samples are stable for long time.

Endometrial biopsy, CA125, HE4, LH, FSH, Progesterone.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login